Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2024 07:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024

SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
May 15, 2024 07:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

Continued progress enrolling in its VMT-α-NET and VMT01 clinical trialsDisclosed a new internally discovered molecule that targets fibroblast activation protein-αAnnounced the in-licensing of a...
May 03, 2024 07:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics to Participate at Upcoming May Investor Conferences

SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
May 02, 2024 07:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results

SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
April 30, 2024 07:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs

SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
April 08, 2024 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics to Participate at Upcoming April Investor Conferences

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
March 28, 2024 07:30 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
March 18, 2024 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma

SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
March 11, 2024 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024

SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
March 05, 2024 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility

SEATTLE, March 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...